ZOLGENSMA INCAL Trademark

Trademark Overview


On Monday, January 29, 2024, a trademark application was filed for ZOLGENSMA INCAL with the United States Patent and Trademark Office. The USPTO has given the ZOLGENSMA INCAL trademark a serial number of 79392220. The federal status of this trademark filing is EXAMINERS AMENDMENT - MAILED as of Monday, March 17, 2025. This trademark is owned by Novartis AG. The ZOLGENSMA INCAL trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations and gene therapy products in the nature of injectable biological preparations for the treatment of genetic, neurological, motor neuron, and neuromuscular diseases, disorders, and conditions; pharmaceutical preparations and gene therapy products in the nature of biological preparations containing genetic materials, sold as a unit, for the treatment of spinal muscular atrophy, loss of motor neurons, muscle degeneration, muscle weakness, and paralysis; gene therapy preparations in the nature of biological preparations containing genetic materials, sold as a unit, for sustained survival motor neuron protein expression being for the treatment of spinal muscular atrophy, loss of motor neurons, muscle degeneration, muscle weakness, and paralysis
zolgensma incal

General Information


Serial Number79392220
Word MarkZOLGENSMA INCAL
Filing DateMonday, January 29, 2024
Status647 - EXAMINERS AMENDMENT - MAILED
Status DateMonday, March 17, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesPharmaceutical preparations and gene therapy products in the nature of injectable biological preparations for the treatment of genetic, neurological, motor neuron, and neuromuscular diseases, disorders, and conditions; pharmaceutical preparations and gene therapy products in the nature of biological preparations containing genetic materials, sold as a unit, for the treatment of spinal muscular atrophy, loss of motor neurons, muscle degeneration, muscle weakness, and paralysis; gene therapy preparations in the nature of biological preparations containing genetic materials, sold as a unit, for sustained survival motor neuron protein expression being for the treatment of spinal muscular atrophy, loss of motor neurons, muscle degeneration, muscle weakness, and paralysis

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, March 29, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameNovartis AG
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCH

Trademark Events


Event DateEvent Description
Thursday, March 28, 2024SN ASSIGNED FOR SECT 66A APPL FROM IB
Tuesday, April 2, 2024APPLICATION FILING RECEIPT MAILED
Monday, April 8, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, April 8, 2024TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Monday, April 8, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, April 8, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, April 8, 2024TEAS CHANGE OF OWNER ADDRESS RECEIVED
Monday, April 8, 2024APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Friday, August 9, 2024ASSIGNED TO EXAMINER
Monday, December 16, 2024PRIORITY ACTION WRITTEN
Monday, December 16, 2024PRIORITY ACTION E-MAILED
Friday, March 29, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, December 16, 2024NOTIFICATION OF PRIORITY ACTION E-MAILED
Tuesday, December 17, 2024NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Thursday, January 2, 2025REFUSAL PROCESSED BY MPU
Friday, January 17, 2025REFUSAL PROCESSED BY IB
Monday, March 17, 2025EXAMINER'S AMENDMENT ENTERED
Monday, March 17, 2025NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Monday, March 17, 2025EXAMINERS AMENDMENT E-MAILED
Monday, March 17, 2025EXAMINERS AMENDMENT -WRITTEN
Thursday, January 2, 2025NON-FINAL ACTION MAILED - REFUSAL SENT TO IB